We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Initial phase 2 data show improvement in Bullous ...
Please provide your email address to receive an email when new articles are posted on . Of 146 patients treated with dupilumab, 127 achieved disease control within 4 weeks. Complete remission was ...
Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...
The fully recruited Phase II trial of nomacopan for treatment of mild-to-moderate BP was a six-week open-label single-arm study evaluating safety and efficacy in 9 patients (7 with moderate severity, ...
Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...
Patients with BP will often go into remission if young, usually less than 65 years old, and in good health, but erupting blisters can continue for 10 or more years. About half of patients go into ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...
A 55-year-old man presents to the clinic with multiple tense bullae diffusely involving his trunk and extremities that overlie urticarial plaques. The patient states that for the past 4 weeks, his ...
Dear Dr. Roach: I was recently diagnosed with bullous pemphigoid, and the dermatologist recommended 10 mg prednisone. I was hoping you could recommend a different medication. — R.M. Answer: Bullous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback